MHRA approves licence extension for enzalutamide

Additional indication is for treatment of metastatic hormone-sensitive prostate cancer. Approval was based on results from Phase III ARCHES trial which showed use with androgen deprivation therapy (ADT) reduced risk of radiographic progression or death by 61% vs ADT alone.

Source:

PharmaTimes